Retrospective multicenter evaluation of oral step-down versus intravenous carbapenem treatment of extended-spectrum beta-lactamase-producing Escherichia coli urinary tract infections
Abstract
Objectives: This study evaluated whether treatment with oral step-down therapy compared with intravenous carbapenems alone for extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli urinary tract infections (UTIs) impacted patient venous catheter days and clinical outcomes.
Methods: This multicenter retrospective study at six different hospitals in a large health system included adults (≥ 18 years) admitted for ≥ 24 hours with ≥ 1 documented UTI symptom, a ceftriaxone-resistant Escherichia coli urine culture, and receipt of ≥ 1 dose of meropenem or ertapenem between August 2022 and July 2025. The primary outcome was median venous catheter line days directly associated with antibiotic use inpatient and outpatient. Secondary outcomes included pharmacist antibiotic intervention, incidence of antibiotic-related adverse events, hospital length of stay, duration of therapy, inpatient catheter line days, projected outpatient catheter line days, presence of peripherally inserted central catheter or midline, central line-associated bloodstream infection, and treatment failure (defined as escalation of antibiotics, in-hospital mortality, urgent care/emergency department visit or readmission, or recurrence of symptomatic UTI with ESBL Escherichia coli within 30 days).
Results: 120 patients were included, with 60 in the oral step-down and carbapenem groups, respectively. Primary outcome of median venous catheter days in the oral step-down group was 0 (IQR 0-0) vs 5 (IQR 0-7)…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.